by MM360 Staff | Jul 3, 2025 | Uncategorized
Source: CureToday articles The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program. Read More
by Lucas Laboy | Jul 2, 2025 | Uncategorized
The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome...
by MM360 Staff | Jun 27, 2025 | Uncategorized
Source: CureToday articles Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting. Read More
by MM360 Staff | Jun 26, 2025 | Uncategorized
Source: CureToday articles I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened doors to adventure and connection. Read More
by MM360 Staff | Jun 9, 2025 | Uncategorized
Source: CureToday articles Michelle Kirschner discusses the how patients can foster a strong network of supporters from diagnosis through survivorship. Read More
by MM360 Staff | Jun 9, 2025 | Uncategorized
Source: CureToday articles Natalie Schnaitmann discusses the importance of self-advocacy and access to second opinions when symptoms are dismissed among young women with cancer. Read More